The three-year study of Ebglyss saw an additional 83% of dermatitis patients achieving ‘almost clear’ skin using the single ...

Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved ...

Eli Lilly (NYSE:LLY) on Friday said that its recently approved eczema therapy Ebglyss led to complete skin clearance in 50% ...

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...

Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.

Ebglyss (lebrikizumab-lbkz) is a prescription drug used to treat atopic dermatitis in certain situations. Ebglyss comes as a liquid solution that you inject under your skin. Ebglyss is used in ...

New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic ...

Lilly added that the study also showed Ebglyss was able to achieve meaningful improvements in patients with ...

At three years, 50% of patients on Ebglyss maintenance dosing achieved complete skin clearance, while 87% had almost-clear skin. Over 83% of Week 16 responders did not need additional topical ...

(RTTNews) - Eli Lilly and Co. (LLY) announced that its Ebglyss monotherapy monthly injection demonstrated sustained and deep responses in patients with moderate-to-severe atopic dermatitis over ...

Eli Lilly (NYSE:LLY) on Friday said that its recently approved eczema therapy Ebglyss led to complete skin clearance in 50% of individuals who took part in a long-term extension study. Citing data ...